Rhenman & Partners Asset Management’s Royalty Pharma RPRX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.2M	Buy	233,000 +26,500	+13%	+$1.16M	1.38%	27
2025 Q4	$7.98M	Sell	206,500 -52,000	-20%	-$1.98M	0.75%	53
2025 Q3	$9.12M	Sell	258,500 -85,500	-25%	-$3.1M	1.01%	37
2025 Q2	$12.4M	Sell	344,000 -67,000	-16%	-$2.22M	1.57%	25
2025 Q1	$12.8M	Sell	411,000 -184,000	-31%	-$5.83M	1.47%	28
2024 Q4	$15.2M	Sell	595,000 -18,500	-3%	-$491K	1.56%	23
2024 Q3	$17.4M	Buy	613,500 +68,803	+13%	+$1.91M	1.41%	24
2024 Q2	$14.4M	Hold	544,697	–	–	1.38%	25
2024 Q1	$16.5M	Buy	544,697 +115,000	+27%	+$3.39M	1.57%	25
2023 Q4	$12.1M	Buy	429,697 +279,697	+186%	+$7.69M	1.21%	32
2023 Q3	$4.07M	Hold	150,000	–	–	0.44%	58
2023 Q2	$4.61M	Sell	150,000 -15,000	-9%	-$508K	0.49%	58
2023 Q1	$5.99M	Sell	165,000 -50,000	-23%	-$1.85M	0.66%	51
2022 Q4	$8.5M	Hold	215,000	–	–	0.89%	43
2022 Q3	$9.1M	Buy	215,000 +65,000	+43%	+$2.78M	0.95%	40
2022 Q2	$6.31M	Buy	+150,000	New	+$6.15M	0.72%	47
2021 Q2	–	Sell	-130,000	Closed	-$5.67M	–	98
2021 Q1	$5.67M	Sell	130,000 -120,000	-48%	-$5.69M	0.4%	70
2020 Q4	$12.5M	Buy	+250,000	New	+$10.6M	1.02%	43

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rhenman & Partners Asset Management's RPRX Position: Q1 2026 in Review

Rhenman & Partners Asset Management increased its Royalty Pharma (RPRX) stake by 13% in Q1 2026, buying an estimated $1.16M and bringing the position to 233,000 shares worth $11.2M. The position accounts for 1.38% of the portfolio, ranked #27.

Rhenman & Partners Asset Management first reported a position in RPRX in Q4 2020 and has held it in 18 quarters since. The position peaked at $17.4M in Q3 2024. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Rhenman & Partners Asset Management held 233,000 shares of Royalty Pharma worth $11.2M as of Q1 2026.
Rhenman & Partners Asset Management bought 26,500 Royalty Pharma shares in Q1 2026, an estimated $1.16M.
Royalty Pharma made up 1.38% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #27 holding.
Rhenman & Partners Asset Management first reported a position in Royalty Pharma in Q4 2020 and has held it in 18 quarters since.
Rhenman & Partners Asset Management's Royalty Pharma position peaked at $17.4M in Q3 2024.
588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.